Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14190918 | 1.00 | LMNA (0.63) | LMNAKMT2ANFE2L2MAPTRAB9A | |
| SCHEMBL4376236 | 0.90 | HPGD (0.67) | LMNAKMT2ANFE2L2MAPTRAB9A | |
| SCHEMBL14190943 | 0.90 | HPGD (0.67) | LMNAKMT2ANFE2L2MAPTRAB9A | |
| SCHEMBL13635985 | 0.85 | KDM4E (0.50) | LMNAMAPTHPGDKDM4EALDH1A1 | |
| SCHEMBL4384479 | 0.85 | KDM4E (0.50) | LMNAMAPTHPGDKDM4EALDH1A1 | |
| SCHEMBL4380520 | 0.80 | GAA (0.61) | LMNAKMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL14190916 | 0.80 | GAA (0.61) | LMNAKMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL14218138 | 0.80 | LMNA (0.62) | LMNAKMT2ANFE2L2MAPTHPGD | |
| SCHEMBL29913258 | 0.79 | NFE2L2 (0.64) | LMNAKMT2ANFE2L2HPGDKDM4E | |
| SCHEMBL13039675 | 0.77 | KDM4E (0.59) | LMNAKMT2AHPGDKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1421071-B1 | SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-11-18 | — | — | EP | claimed |
| EP-1421071-B1 | SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20080113968-A1 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | US | disclosed |
| US-7208497-B2 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2007-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113968-A1 | Substituted piperazines and diazepanes | HRH3, HRH4, HRH1 | LMNA 4304/4885KMT2A 295/4885NFE2L2 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.